MersV1, Ncbi, Merge, bibRecord, 001D06

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.

Identifieur interne : 001D06 ( Ncbi/Merge ); précédent : 001D05; suivant : 001D07

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.

Auteurs : John H. Beigel [États-Unis] ; Jocelyn Voell [États-Unis] ; Parag Kumar [États-Unis] ; Kanakatte Raviprakash [États-Unis] ; Hua Wu [États-Unis] ; Jin-An Jiao [États-Unis] ; Eddie Sullivan [États-Unis] ; Thomas Luke [États-Unis] ; Richard T. Davey [États-Unis]

Source :

The Lancet. Infectious diseases [ 1474-4457 ] ; 2018.

RBID : pubmed:29329957

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Animal génétiquement modifié, Animaux, Anticorps antiviraux (administration et posologie), Anticorps antiviraux (effets indésirables), Bovins, Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Femelle, Humains, Immunisation passive (), Immunisation passive (effets indésirables), Immunoglobuline G (administration et posologie), Immunoglobuline G (effets indésirables), Jeune adulte, Mâle, Méthode en double aveugle, National Institutes of Health (USA), Perfusions veineuses, Placebo (administration et posologie), Volontaires sains, États-Unis d'Amérique, Études de suivi.
MESH :
- administration et posologie : Anticorps antiviraux, Immunoglobuline G, Placebo.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Anticorps antiviraux, Immunisation passive, Immunoglobuline G.
- immunologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adulte, Adulte d'âge moyen, Animal génétiquement modifié, Animaux, Bovins, Femelle, Humains, Immunisation passive, Jeune adulte, Mâle, Méthode en double aveugle, National Institutes of Health (USA), Perfusions veineuses, Volontaires sains, États-Unis d'Amérique, Études de suivi.
Wicri :
- geographic : États-Unis.

English descriptors

KwdEn :
- Adult, Animals, Animals, Genetically Modified, Antibodies, Viral (administration & dosage), Antibodies, Viral (adverse effects), Cattle, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female, Follow-Up Studies, Healthy Volunteers, Humans, Immunization, Passive (adverse effects), Immunization, Passive (methods), Immunoglobulin G (administration & dosage), Immunoglobulin G (adverse effects), Infusions, Intravenous, Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus (immunology), National Institutes of Health (U.S.), Placebos (administration & dosage), United States, Young Adult.
MESH :
- chemical , administration & dosage : Antibodies, Viral, Immunoglobulin G, Placebos.
- chemical , adverse effects : Antibodies, Viral, Immunoglobulin G.
- geographic : United States.
- adverse effects : Immunization, Passive.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- immunology : Middle East Respiratory Syndrome Coronavirus.
- methods : Immunization, Passive.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- Adult, Animals, Animals, Genetically Modified, Cattle, Double-Blind Method, Female, Follow-Up Studies, Healthy Volunteers, Humans, Infusions, Intravenous, Male, Middle Aged, National Institutes of Health (U.S.), Young Adult.

Abstract

Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine.

DOI: 10.1016/S1473-3099(18)30002-1
PubMed: 29329957

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000A25
to stream PubMed, to step Curation: 000A25
to stream PubMed, to step Checkpoint: 000772

Links to Exploration step

pubmed:29329957

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.</title>
<author><name sortKey="Beigel, John H" sort="Beigel, John H" uniqKey="Beigel J" first="John H" last="Beigel">John H. Beigel</name>
<affiliation wicri:level="2"><nlm:affiliation>Leidos Biomedical Research Inc, Frederick, MD, USA. Electronic address: jbeigel@niaid.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Leidos Biomedical Research Inc, Frederick, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Voell, Jocelyn" sort="Voell, Jocelyn" uniqKey="Voell J" first="Jocelyn" last="Voell">Jocelyn Voell</name>
<affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kumar, Parag" sort="Kumar, Parag" uniqKey="Kumar P" first="Parag" last="Kumar">Parag Kumar</name>
<affiliation wicri:level="2"><nlm:affiliation>National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raviprakash, Kanakatte" sort="Raviprakash, Kanakatte" uniqKey="Raviprakash K" first="Kanakatte" last="Raviprakash">Kanakatte Raviprakash</name>
<affiliation wicri:level="2"><nlm:affiliation>Naval Medical Research Center, Silver Spring, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Naval Medical Research Center, Silver Spring, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wu, Hua" sort="Wu, Hua" uniqKey="Wu H" first="Hua" last="Wu">Hua Wu</name>
<affiliation wicri:level="2"><nlm:affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SAB Biotherapeutics Inc, Sioux Falls, SD</wicri:regionArea>
<placeName><region type="state">Dakota du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jiao, Jin An" sort="Jiao, Jin An" uniqKey="Jiao J" first="Jin-An" last="Jiao">Jin-An Jiao</name>
<affiliation wicri:level="2"><nlm:affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SAB Biotherapeutics Inc, Sioux Falls, SD</wicri:regionArea>
<placeName><region type="state">Dakota du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sullivan, Eddie" sort="Sullivan, Eddie" uniqKey="Sullivan E" first="Eddie" last="Sullivan">Eddie Sullivan</name>
<affiliation wicri:level="2"><nlm:affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SAB Biotherapeutics Inc, Sioux Falls, SD</wicri:regionArea>
<placeName><region type="state">Dakota du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Thomas" sort="Luke, Thomas" uniqKey="Luke T" first="Thomas" last="Luke">Thomas Luke</name>
<affiliation wicri:level="2"><nlm:affiliation>The Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Davey, Richard T" sort="Davey, Richard T" uniqKey="Davey R" first="Richard T" last="Davey">Richard T. Davey</name>
<affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29329957</idno>
<idno type="pmid">29329957</idno>
<idno type="doi">10.1016/S1473-3099(18)30002-1</idno>
<idno type="wicri:Area/PubMed/Corpus">000A25</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A25</idno>
<idno type="wicri:Area/PubMed/Curation">000A25</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A25</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000772</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000772</idno>
<idno type="wicri:Area/Ncbi/Merge">001D06</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.</title>
<author><name sortKey="Beigel, John H" sort="Beigel, John H" uniqKey="Beigel J" first="John H" last="Beigel">John H. Beigel</name>
<affiliation wicri:level="2"><nlm:affiliation>Leidos Biomedical Research Inc, Frederick, MD, USA. Electronic address: jbeigel@niaid.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Leidos Biomedical Research Inc, Frederick, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Voell, Jocelyn" sort="Voell, Jocelyn" uniqKey="Voell J" first="Jocelyn" last="Voell">Jocelyn Voell</name>
<affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kumar, Parag" sort="Kumar, Parag" uniqKey="Kumar P" first="Parag" last="Kumar">Parag Kumar</name>
<affiliation wicri:level="2"><nlm:affiliation>National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raviprakash, Kanakatte" sort="Raviprakash, Kanakatte" uniqKey="Raviprakash K" first="Kanakatte" last="Raviprakash">Kanakatte Raviprakash</name>
<affiliation wicri:level="2"><nlm:affiliation>Naval Medical Research Center, Silver Spring, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Naval Medical Research Center, Silver Spring, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wu, Hua" sort="Wu, Hua" uniqKey="Wu H" first="Hua" last="Wu">Hua Wu</name>
<affiliation wicri:level="2"><nlm:affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SAB Biotherapeutics Inc, Sioux Falls, SD</wicri:regionArea>
<placeName><region type="state">Dakota du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jiao, Jin An" sort="Jiao, Jin An" uniqKey="Jiao J" first="Jin-An" last="Jiao">Jin-An Jiao</name>
<affiliation wicri:level="2"><nlm:affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SAB Biotherapeutics Inc, Sioux Falls, SD</wicri:regionArea>
<placeName><region type="state">Dakota du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sullivan, Eddie" sort="Sullivan, Eddie" uniqKey="Sullivan E" first="Eddie" last="Sullivan">Eddie Sullivan</name>
<affiliation wicri:level="2"><nlm:affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>SAB Biotherapeutics Inc, Sioux Falls, SD</wicri:regionArea>
<placeName><region type="state">Dakota du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Thomas" sort="Luke, Thomas" uniqKey="Luke T" first="Thomas" last="Luke">Thomas Luke</name>
<affiliation wicri:level="2"><nlm:affiliation>The Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Davey, Richard T" sort="Davey, Richard T" uniqKey="Davey R" first="Richard T" last="Davey">Richard T. Davey</name>
<affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Lancet. Infectious diseases</title>
<idno type="eISSN">1474-4457</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Animals</term>
<term>Animals, Genetically Modified</term>
<term>Antibodies, Viral (administration & dosage)</term>
<term>Antibodies, Viral (adverse effects)</term>
<term>Cattle</term>
<term>Double-Blind Method</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Drug-Related Side Effects and Adverse Reactions (pathology)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Healthy Volunteers</term>
<term>Humans</term>
<term>Immunization, Passive (adverse effects)</term>
<term>Immunization, Passive (methods)</term>
<term>Immunoglobulin G (administration & dosage)</term>
<term>Immunoglobulin G (adverse effects)</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>National Institutes of Health (U.S.)</term>
<term>Placebos (administration & dosage)</term>
<term>United States</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animal génétiquement modifié</term>
<term>Animaux</term>
<term>Anticorps antiviraux (administration et posologie)</term>
<term>Anticorps antiviraux (effets indésirables)</term>
<term>Bovins</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Effets secondaires indésirables des médicaments (anatomopathologie)</term>
<term>Effets secondaires indésirables des médicaments (épidémiologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunisation passive ()</term>
<term>Immunisation passive (effets indésirables)</term>
<term>Immunoglobuline G (administration et posologie)</term>
<term>Immunoglobuline G (effets indésirables)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>National Institutes of Health (USA)</term>
<term>Perfusions veineuses</term>
<term>Placebo (administration et posologie)</term>
<term>Volontaires sains</term>
<term>États-Unis d'Amérique</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
<term>Placebos</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
<term>Placebo</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunization, Passive</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunisation passive</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Passive</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Animals</term>
<term>Animals, Genetically Modified</term>
<term>Cattle</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Healthy Volunteers</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>National Institutes of Health (U.S.)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animal génétiquement modifié</term>
<term>Animaux</term>
<term>Bovins</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunisation passive</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>National Institutes of Health (USA)</term>
<term>Perfusions veineuses</term>
<term>Volontaires sains</term>
<term>États-Unis d'Amérique</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29329957</PMID>
<DateCompleted><Year>2019</Year>
<Month>02</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>4</Issue>
<PubDate><Year>2018</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>The Lancet. Infectious diseases</Title>
<ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.</ArticleTitle>
<Pagination><MedlinePgn>410-418</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1473-3099(18)30002-1</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(18)30002-1</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine.</AbstractText>
<AbstractText Label="METHODS">We did a phase 1 double-blind, placebo-controlled, single-dose escalation trial at the National Institutes of Health Clinical Center. We recruited healthy participants aged 18-60 years who had normal laboratory parameters at enrolment, a body-mass index of 19-32 kg/m<sup>2</sup>
, and a creatinine clearance of 70 mL/min or more, and who did not have any chronic medical problems that required daily oral medications, a positive rheumatoid factor (≥15 IU/mL), IgA deficiency (<7 mg/dL), or history of allergy to intravenous immunoglobulin or human blood products. Participants were randomly assigned by a computer-generated table, made by a masked pharmacist, to one of six cohorts (containing between three and ten participants each). Cohorts 1 and 2 had three participants, randomly assigned 2:1 to receive active drug SAB-301 versus normal saline placebo; cohorts 3 and 4 had six participants randomised 2:1; and cohorts 5 and 6 had ten participants, randomised 4:1. Participants received 1 mg/kg, 2·5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 50 mg/kg of SAB-301, or equivalent volume placebo (saline control), on day 0, and were followed up by clinical, laboratory, and pharmacokinetic assessments on days 1, 3, 7, 21, 42, and 90. The primary outcome was safety, and immunogenicity was a secondary outcome. We analysed the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02788188.</AbstractText>
<AbstractText Label="FINDINGS">Between June 2, 2016, and Jan 4, 2017, we screened 43 participants, of whom 38 were eligible and randomly assigned to receive SAB-301 (n=28) or placebo (n=10). 97 adverse events were reported: 64 adverse events occurred in 23 (82%) of 28 participants receiving SAB-301 (mean 2·3 adverse events per participant). 33 adverse events occurred in all ten participants receiving placebo (mean 3·3 adverse events per participant). The most common adverse events were headache (n=6 [21%] in participants who received SAB-301 and n=2 [20%] in those receiving placebo), albuminuria (n=5 [18%] vs n=2 [20%]), myalgia (n=3 [11%] vs n=1 [10%]), increased creatine kinase (n=3 [11%] vs 1 [10%]), and common cold (n=3 [11%] vs n=2 [20%]). There was one serious adverse event (hospital admission for suicide attempt) in one participant who received 50 mg/kg of SAB-301. The area under the concentration-time curve (AUC) in the 50 mg/kg dose (27 498 μg × days per mL) is comparable to the AUC that was associated with efficacy in a preclinical model.</AbstractText>
<AbstractText Label="INTERPRETATION">Single infusions of SAB-301 up to 50 mg/kg appear to be safe and well tolerated in healthy participants. Human immunoglobulin derived from transchromosomic cattle could offer a new platform technology to produce fully human polyclonal IgG antibodies for other medical conditions.</AbstractText>
<AbstractText Label="FUNDING">National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Biomedical Advanced Research and Development Authority.</AbstractText>
<CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beigel</LastName>
<ForeName>John H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Leidos Biomedical Research Inc, Frederick, MD, USA. Electronic address: jbeigel@niaid.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Voell</LastName>
<ForeName>Jocelyn</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Parag</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Raviprakash</LastName>
<ForeName>Kanakatte</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Naval Medical Research Center, Silver Spring, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Hua</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jiao</LastName>
<ForeName>Jin-An</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sullivan</LastName>
<ForeName>Eddie</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>SAB Biotherapeutics Inc, Sioux Falls, SD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Luke</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>The Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Davey</LastName>
<ForeName>Richard T</ForeName>
<Initials>RT</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT02788188</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y"><Grant><GrantID>Z99 AI999999</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN272201100022C</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>ZIA AI000984-10</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN261200800001C</GrantID>
<Acronym>RC</Acronym>
<Agency>CCR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN272201100022I</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>HHSN261200800001E</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>01</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Lancet Infect Dis</MedlineTA>
<NlmUniqueID>101130150</NlmUniqueID>
<ISSNLinking>1473-3099</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2018 Apr;18(4):361-363</RefSource>
<PMID Version="1">29329956</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>08</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>10</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>11</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29329957</ArticleId>
<ArticleId IdType="pii">S1473-3099(18)30002-1</ArticleId>
<ArticleId IdType="doi">10.1016/S1473-3099(18)30002-1</ArticleId>
<ArticleId IdType="pmc">PMC5871563</ArticleId>
<ArticleId IdType="mid">NIHMS935573</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2017 Jun;5(6):500-511</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28522352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2017 Oct;45(10 ):1683-1695</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28787295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2016 Feb 17;8(326):326ra21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26888429</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2017 Feb 9;376(6):584-594</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28177862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2016 Sep;22(9):1554-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27532807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Hematol. 2015 Nov;22(6):521-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26457963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2005 Nov;56(5):919-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16183666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Jun 24;10(6):e0130699</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26107496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2016 Feb 15;62(4):477-483</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26565003</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Dakota du Sud</li>
<li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Beigel, John H" sort="Beigel, John H" uniqKey="Beigel J" first="John H" last="Beigel">John H. Beigel</name>
</region>
<name sortKey="Davey, Richard T" sort="Davey, Richard T" uniqKey="Davey R" first="Richard T" last="Davey">Richard T. Davey</name>
<name sortKey="Jiao, Jin An" sort="Jiao, Jin An" uniqKey="Jiao J" first="Jin-An" last="Jiao">Jin-An Jiao</name>
<name sortKey="Kumar, Parag" sort="Kumar, Parag" uniqKey="Kumar P" first="Parag" last="Kumar">Parag Kumar</name>
<name sortKey="Luke, Thomas" sort="Luke, Thomas" uniqKey="Luke T" first="Thomas" last="Luke">Thomas Luke</name>
<name sortKey="Raviprakash, Kanakatte" sort="Raviprakash, Kanakatte" uniqKey="Raviprakash K" first="Kanakatte" last="Raviprakash">Kanakatte Raviprakash</name>
<name sortKey="Sullivan, Eddie" sort="Sullivan, Eddie" uniqKey="Sullivan E" first="Eddie" last="Sullivan">Eddie Sullivan</name>
<name sortKey="Voell, Jocelyn" sort="Voell, Jocelyn" uniqKey="Voell J" first="Jocelyn" last="Voell">Jocelyn Voell</name>
<name sortKey="Wu, Hua" sort="Wu, Hua" uniqKey="Wu H" first="Hua" last="Wu">Hua Wu</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D06 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001D06 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:29329957
   |texte=   Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:29329957" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki